Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts

Goletz C, Lischke T, Harnack U, Schiele P, Danielczyk A, Rühmann J and Goletz S (2018) Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Front. Immunol. 9:1614. doi: 10.3389/fimmu.2018.01614

Read more
Phase I study of tomuzotuximab, a glycoemgineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

Walter Fiedler, Sara Cresta, Henning Schulze-Bergkamen, Sara De Dosso, Jens Weidmann, Anna Tessari, Hans Baumeister, Antje Danielczyk, Bruno Dietrich, Steffen Goletz, Alfredo Zurlo, Marc Salzberg, Cristiana Sessa, Luca Gianni

Read more